ATOS | Informative

ATOS

It completed wave 3, and now wave 4 has started. It is expected to reach the 1.08 area soon, which aligns precisely with the Fibonacci retracements. After that, it should initiate wave 5, with the initial target being 1.60, followed by 2.10, which is a significant key level from 2021.

There is a possibility that market manipulators (MM) will create volatility and attempt to discourage retail investors. Considering the Fibonacci levels and historical support and resistance lines, there is even a chance of it dropping to the $1 area. However, it's important to maintain faith as the overall trajectory is upward. More retracement could potentially result in a higher upside possibility.

The Company:
ATOS is the ticker symbol for Atossa Therapeutics Inc., a biopharmaceutical company focused on the development of novel therapeutics for breast cancer and other breast conditions. The company's primary area of research is the development of therapies using its proprietary Endoxifen technology.

Endoxifen is an active metabolite of the drug tamoxifen, which is commonly used in the treatment of hormone receptor-positive breast cancer. Atossa Therapeutics is investigating the use of its proprietary formulations of topical and oral Endoxifen for various indications, including breast cancer prevention and the reduction of mammographic breast density.